Скачать или смотреть Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer

David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab (Avastin) plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

There is still not enough data to say there is synergy between these 2 agents, but so far there has been an increase in progression-free survival (PFS) and response rates compared to standard cytotoxic chemotherapies.

Mirvetuximab soravtansine alone has made a clear impact on heavily pretreated, platinum-resistant patients with ovarian cancer, with PFS approaching 10 months, O’Malley says.

For more resources and information regarding anticancer targeted therapies in ovarian cancer: http://targetedonc.com/resource-cente...